What You Should Know:
- Sonde Health, a Boston, MA-based health technology company committed to bringing accessible health monitoring to everyone raises $19.25 million in a Series B investment round led by Partners Investment, with participation from NEOM Company, KT Corporation, and existing investors, including co-founder PureTech Health and M Ventures.
- The AI vocal biomarker company will use the funding to accelerate its commercial growth, expand its platform into new health
Read More
Biomarkers| Big Data| News, Analysis, Insights - HIT Consultant
Can Doctors Objectively Quantify and Measure Pain?
Millions of Americans live with acute and chronic pain that affects every aspect of their lives. Pain by itself is an important marker of how a patient is feeling and indicates what kind of medical intervention might be necessary. The healthcare industry needs a clinically acceptable way to objectively measure pain and since pain is a very complex mixture of biochemistry and genetics and it’s unlikely that a laboratory test that directly quantifies pain will be developed.
Doctors
Read More
New Liquid Biopsy Detects Breast Cancer at Its Earliest Stages
What You Should Know:
- Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes.
- Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be achieved based on symptoms or mammography.
Non-Invasive Blood-Based Platform Delivers Promising Data on Detecting Breast Cancer At It’s Earliest Stages
Exai Bio is a
Read More
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
How Biosensing Tech Can Alleviate Dehydration in Older Adults
For most adults, the first sign of dehydration is feeling thirsty. However, as we age, our thirst sensation naturally weakens, which means older people may not know that they need more fluids until they’re typically underhydrated, putting them at a higher risk of clinical dehydration.
Other age-related physiological changes can also impact a person’s ability to remain hydrated, such as a decline in kidney function. Indeed, renal function begins to diminish around the age of 50. This is due
Read More
ConcertAI CEO Talks COVID-19 & The De-Risking of Technology to Keep Trials Moving
Nothing like it had ever happened before – a global slowdown in new study starts and a massive decrease in trial accruals for open studies. The turn of events was a shock for sponsors and providers. Sudden disruptions on that scale rarely hit multiple players in an ecosystem at the same time. But that’s exactly what happened at the intersection of clinical care and clinical development during the pandemic. Researchers and clinicians were forced to change how they operated trials, and
Read More
Numares Health & Mayo Clinic Expands AI-Enabled Diagnostic Testing Collaboration
What You Should Know:
- Mayo Clinic and Numares Health have expanded their collaboration recently to develop AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
- The expanded collaboration builds on Mayo Clinic's clinical research support for Numares Health to include an innovative convertible equity investment.
AI-Enabled
Read More
JPMorgan Establishes Life Sciences Private Equity Division
What You Should Know:
- J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.
- The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity,
Read More
Viome Raises $67M to Expand Microbiome & At-Home Test Kits
What You Should Know:
- Viome Life Sciences, a mission-driven digital health company, announced additional $67M in funding toward its Series C round.
- Led by Bold Capital Group, the $67M raise brings the company’s total funding to over $150M and will be used to support the development of its at-home tests that leverage precision nutrition to improve health and increase longevity by addressing the epidemic of chronic diseases, cancers, and aging.
- Viome will expand its proprietary mRNA
Read More
Eyenuk Raises $26M for AI-Powered Eye Screening & Predictive Biomarkers
What You Should Know:
- Eyenuk, Inc., a global artificial intelligence (AI) digital health company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced it has secured $26 million in a Series A financing round, bringing the Company’s total funding to over $43 million.
- The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall
Read More
